Statera BioPharma (STU:7CB) Debt-to-Equity : -0.72 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Debt-to-Equity?

Statera BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €6.79 Mil. Statera BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.69 Mil. Statera BioPharma's Total Stockholders Equity for the quarter that ended in Sep. 2022 was €-10.34 Mil. Statera BioPharma's debt to equity for the quarter that ended in Sep. 2022 was -0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Statera BioPharma's Debt-to-Equity or its related term are showing as below:

STU:7CB' s Debt-to-Equity Range Over the Past 10 Years
Min: -10.37 Med: -0.64 Max: 0.23
Current: -0.72

During the past 3 years, the highest Debt-to-Equity Ratio of Statera BioPharma was 0.23. The lowest was -10.37. And the median was -0.64.

STU:7CB's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs STU:7CB: -0.72

Statera BioPharma Debt-to-Equity Historical Data

The historical data trend for Statera BioPharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Debt-to-Equity Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Debt-to-Equity

-0.43

-0.55

-10.37

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial						0.23	-10.37	-2.87	-1.08	-0.72

Competitive Comparison of Statera BioPharma's Debt-to-Equity

For the Biotechnology subindustry, Statera BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Debt-to-Equity falls into.

Statera BioPharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Statera BioPharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.275	+	10.116)	/	-1.388
	=	-10.37

Statera BioPharma's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.787	+	0.693)	/	-10.343
	=	-0.72

Statera BioPharma (STU:7CB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Statera BioPharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (STU:7CB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines